Inhibition of matrix metalloproteinase-2 modulates malignant behaviour of oral squamous cell carcinoma cells.
MMP2
keratinocytes
matrix metalloproteinases
oral cancer
Journal
Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology
ISSN: 1600-0714
Titre abrégé: J Oral Pathol Med
Pays: Denmark
ID NLM: 8911934
Informations de publication
Date de publication:
Mar 2021
Mar 2021
Historique:
revised:
16
12
2019
received:
11
08
2019
accepted:
04
01
2020
pubmed:
12
1
2020
medline:
20
3
2021
entrez:
12
1
2020
Statut:
ppublish
Résumé
Matrix metalloproteinases (MMPs) play a crucial role in the malignant phenotype of cancer cells. In particular, active levels of MMP2 in cancer cells have been associated with invasion and metastasis through the degradation of basement membrane extracellular matrix proteins. However, little is known about the role of this potential biomarker in oral cancer. Our aim was to investigate the effect of MMP2 inhibition on OSCC activity in vitro, as well as to assess MMP2 dysregulation in oral cancer samples. Human OSCC cell lines H357 and H400 were tested with the selective MMP2 inhibitor ARP101 and the MMP2 neutralising monoclonal antibody MA5-13590 to assess cell proliferation in vitro using MTS assay. Cell migration at 12/24 h was assessed using a Transwell migration assay. Cell invasion was assessed at 24 h using a Corning Matrigel invasion assay. MMP2 expression was assessed in 208 tissue samples (related to 60 OSCC cases and nine normal control) using tissue microarray (TMA) and further analysed via TCGA. Both ARP101 and MA5-13590 monoclonal antibody reduced cell proliferation in both the cell lines tested. Treatment with 4μg/mL of MMP2 monoclonal antibody showed a significant decrease in cell migration at 24 hours. The administration of ARP101 and monoclonal antibody to H357 and H400 cell lines induced a drastic reduction in cell invasion at 24 h compared to the control. In patients, TCGA analysis demonstrated that oral cancer tissues express significantly higher levels of MMP2 mRNA compared to normal oral tissues. Further, IHC analysis on TMA showed significant difference in MMP2 protein expression between low and high histopathological grade OSCC. We have demonstrated, for the first time, that MMP2 inhibition affects oral cancer cells ability to survive, migrate and invade in vitro. Differences between MMP2 expression in normal and malignant tissues varied. Further research on the role of MMP2 in OSCC and novel mechanisms to inhibit MMP2-dependent pathways should be encouraged.
Sections du résumé
BACKGROUND
BACKGROUND
Matrix metalloproteinases (MMPs) play a crucial role in the malignant phenotype of cancer cells. In particular, active levels of MMP2 in cancer cells have been associated with invasion and metastasis through the degradation of basement membrane extracellular matrix proteins. However, little is known about the role of this potential biomarker in oral cancer. Our aim was to investigate the effect of MMP2 inhibition on OSCC activity in vitro, as well as to assess MMP2 dysregulation in oral cancer samples.
METHODS
METHODS
Human OSCC cell lines H357 and H400 were tested with the selective MMP2 inhibitor ARP101 and the MMP2 neutralising monoclonal antibody MA5-13590 to assess cell proliferation in vitro using MTS assay. Cell migration at 12/24 h was assessed using a Transwell migration assay. Cell invasion was assessed at 24 h using a Corning Matrigel invasion assay. MMP2 expression was assessed in 208 tissue samples (related to 60 OSCC cases and nine normal control) using tissue microarray (TMA) and further analysed via TCGA.
RESULTS
RESULTS
Both ARP101 and MA5-13590 monoclonal antibody reduced cell proliferation in both the cell lines tested. Treatment with 4μg/mL of MMP2 monoclonal antibody showed a significant decrease in cell migration at 24 hours. The administration of ARP101 and monoclonal antibody to H357 and H400 cell lines induced a drastic reduction in cell invasion at 24 h compared to the control. In patients, TCGA analysis demonstrated that oral cancer tissues express significantly higher levels of MMP2 mRNA compared to normal oral tissues. Further, IHC analysis on TMA showed significant difference in MMP2 protein expression between low and high histopathological grade OSCC.
CONCLUSIONS
CONCLUSIONS
We have demonstrated, for the first time, that MMP2 inhibition affects oral cancer cells ability to survive, migrate and invade in vitro. Differences between MMP2 expression in normal and malignant tissues varied. Further research on the role of MMP2 in OSCC and novel mechanisms to inhibit MMP2-dependent pathways should be encouraged.
Substances chimiques
Matrix Metalloproteinase 2
EC 3.4.24.24
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
323-332Informations de copyright
© 2020 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
Références
Kumar M, Nanavati R, Modi TG, Dobariya C. Oral cancer: etiology and risk factors: a review. J Cancer Res Ther. 2016;12(2):458.
Rhodus NL. Oral cancer: leukoplakia and squamous cell carcinoma. Dental Clinics. 2005;49(1):143-165.
Tamamura R, Nagatsuka H, Siar CH, et al. Comparative analysis of basal lamina type IV collagen α chains, matrix metalloproteinases-2 and-9 expressions in oral dysplasia and invasive carcinoma. Acta Histochem. 2013;115(2):113-119.
Rosenthal EL, Matrisian LM. Matrix metalloproteinases in head and neck cancer. Head Neck. 2006;28(7):639-648.
Islam MS, Mohanto NC, Karim MR, et al. Elevated concentrations of serum matrix metalloproteinase-2 and-9 and their associations with circulating markers of cardiovascular diseases in chronic arsenic-exposed individuals. Environmental Health. 2015;14(1):92.
Gialeli C, Theocharis AD, Karamanos NK. Roles of matrix metalloproteinases in cancer progression and their pharmacological targeting. FEBS J. 2011;278(1):16-27.
Björklund M, Koivunen E. Gelatinase-mediated migration and invasion of cancer cells. Biochim Biophys Acta. 2005;1755(1):37-69.
Hassona Y, Cirillo N, Heesom K, Parkinson E, Prime S. Senescent cancer-associated fibroblasts secrete active MMP-2 that promotes keratinocyte dis-cohesion and invasion. Br J Cancer. 2014;111(6):1230-1237.
Prime SS, Nixon SV, Crane IJ, et al. The behaviour of human oral squamous cell carcinoma in cell culture. J Pathol. 1990;160(3):259-269.
Santos MA, Marques SM, Tuccinardi T, Carelli P, Panelli L, Rossello A. Design, synthesis and molecular modeling study of iminodiacetyl monohydroxamic acid derivatives as MMP inhibitors. Bioorg Med Chem. 2006;14:7539-7550.
Jo YK, Park SJ, Shin JH, et al. ARP101, a selective MMP-2 inhibitor, induces autophagy-associated cell death in cancer cells. Biochem Biophys Res Comm. 2011;404(4):1039-1043.
Kim ES, Jo YK, Park SJ, et al. ARP101 inhibits α-MSH-stimulated melanogenesis by regulation of autophagy in melanocytes. FEBS Lett. 2013;587(24):3955-3960.
Yang L, Zheng Z, Zhou Q, et al. miR-155 promotes cutaneous wound healing through enhanced keratinocytes migration by MMP-2. J Mol Histol. 2017;48(2):147-155.
Zhong Y, Lu Y-T, Sun Y, et al. Recent opportunities in matrix metalloproteinase inhibitor drug design for cancer. Expert Opin Drug Discov. 2018;13(1):75-87.
Hoekstra R, Eskens FA, Verweij J. Matrix metalloproteinase inhibitors: current developments and future perspectives. Oncologist. 2001;6(5):415-427.
Winer A, Adams S, Mignatti P. Matrix Metalloproteinase inhibitors in cancer therapy: turning past failures into future successes. Mol Cancer Ther. 2018;17(6):1147-1155.
Fields GB. The rebirth of matrix metalloproteinase inhibitors: moving beyond the dogma. Cells. 2019;8(9):984.
Henriet P, Emonard H. Matrix metalloproteinase-2: Not (just) a "hero" of the past. Biochimie. 2019;166:223-232.
Shrestha B, Bajracharya D, Byatnal AA, Kamath A, Radhakrishnan R. May high MMP-2 and TIMP-2 expressions increase or decrease the aggressivity of oral cancer? Pathol Oncol Res. 2017;23(1):197-206.
Yamada S, Yanamoto S, Naruse T, et al. Skp2 regulates the expression of MMP-2 and MMP-9, and enhances the invasion potential of oral squamous cell carcinoma. Pathol Oncol Res. 2016;22(3):625-632.
Ondruschka C, Buhtz P, Motsch C, et al. Prognostic value of MMP-2, -9 and TIMP-1,-2 immunoreactive protein at the invasive front in advanced head and neck squamous cell carcinomas. Pathol Res Pract. 2002;198(8):509-515.
Ruokolainen H, Pääkkö P, Turpeenniemi-Hujanen T. Tissue and circulating immunoreactive protein for MMP-2 and TIMP-2 in head and neck squamous cell carcinoma-tissue immunoreactivity predicts aggressive clinical course. Mod Pathol. 2006;19(2):208-217.
Yoshizaki T, Maruyama Y, Sato H, Furukawa M. Expression of tissue inhibitor of matrix metalloproteinase-2 correlates with activation of matrix metalloproteinase-2 and predicts poor prognosis in tongue squamous cell carcinoma. Int J Cancer. 2001;95(1):44-50.
Fang CY, Wu CZ, Chen PN, et al. Antimetastatic potentials of salvianolic acid A on oral squamous cell carcinoma by targeting MMP-2 and the c-Raf/MEK/ERK pathway. Environ Toxicol. 2018;33(5):545-554.
Huang YW, Chuang CY, Hsieh YS, et al. Rubus idaeus extract suppresses migration and invasion of human oral cancer by inhibiting MMP-2 through modulation of the Erk1/2 signaling pathway. Environ Toxicol. 2017;32(3):1037-1046.
Cirillo N, Hassona Y, Celentano A, et al. Cancer-associated fibroblasts regulate keratinocyte cell-cell adhesion via TGF-β-dependent pathways in genotype-specific oral cancer. Carcinogenesis. 2017;38(1):76-85.